January 6, 2016
San Diego, Calif., January 6th, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, is pleased to announce that the Company has been selected to deliver a corporate presentation at the 8th annual Biotech Showcase™ conference being held January 11-13, 2016 during the JP Morgan Healthcare Conference in San Francisco, CA.
Joseph E. Payne, President and CEO at Arcturus, will be presenting on Tuesday, January 12, 2016 at 8:15 am PST in the Davidson room of the Parc 55 Hotel.
Payne stated, “I look forward to providing a corporate overview that includes a summary of key 2015 accomplishments, and updates on our internal preclinical messenger RNA therapeutic programs.” He added, “We continue to see multiple business development opportunities available based on Arcturus’ proprietary UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery technology platforms.”
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies – UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (34 patents and patent applications, issued in the U.S. and other countries). Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company’s commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. (A Johnson and Johnson Company) and Ultragenyx Pharmaceuticals, Inc. For more information, visit www.ArcturusRx.com.
About Biotech Showcase™
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Now in its eighth year, Biotech Showcase™ 2016 is expected to attract upwards of 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. The event is being held January 11-13, 2016 in San Francisco, CA at the Parc 55 Hotel.
# # #